Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 158Lymphoma 156Precursor Cell Lymphoblastic Leukemia-Lymphoma 130Lymphoma, Non-Hodgkin 120Leukemia 119Leukemia, Lymphocytic, Chronic, B-Cell 116Multiple Myeloma 115Lymphoma, Large B-Cell, Diffuse 100Leukemia, Myeloid, Acute 97Hodgkin Disease 82Myelodysplastic Syndromes 78Lymphoma, Follicular 74Lymphoma, Mantle-Cell 72Burkitt Lymphoma 66Lymphoma, B-Cell, Marginal Zone 52Melanoma 49Leukemia, Myelogenous, Chronic, BCR-ABL Positive 48Neoplasms 45Recurrence 38Hematologic Neoplasms 34Lymphoma, Large-Cell, Immunoblastic 33Myeloproliferative Disorders 31Congenital Abnormalities 31Waldenstrom Macroglobulinemia 30Neoplasms, Plasma Cell 30Leukemia, Myelomonocytic, Chronic 30Lymphoma, B-Cell 29Primary Myelofibrosis 27Lymphoma, Large-Cell, Anaplastic 27Leukemia, Myeloid, Accelerated Phase 26

Interventions

Nivolumab 11Ipilimumab 6linrodostat 4relatlimab 3Pemetrexed 2tislelizumab 1regorafenib 1ralimetinib 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1gedatolisib 1figitumumab 1efatutazone 1abemaciclib 1Vorinostat 1Tetanus Toxoid 1Tamoxifen 1Sunitinib 1Ranitidine 1Midazolam 1LY2603618 1LY2584702 1Irinotecan 1Gemcitabine 1Fulvestrant 1Dasatinib 1Cyclophosphamide 1Crizotinib 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Cancer × Cyclophosphamide × Clear all
NCT02737475 2022-01-25

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
166 enrolled 57 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡